Deal Watch: BMS Returning IL-12 Candidate To Frequent Partner Dragonfly

The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.

Deal Watch 2021
• Source: Shutterstock

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

While the two biopharmas remain partnered on multiple Tri-Specific Natural Killer cell Engager Therapies (TriNKET) candidates from collaborations dating back to 2017, Dragonfly Therapeutics, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal Watch

More from Deals

Novartis Gains Further Renal Territory With Regulus Acquisition

 

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By 

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

 

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.